Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab-based Immunochemotherapy for Renal Cell Carcinoma
NCT00073879Phase 2Completed
- Sponsor
- Baylor College of Medicine
- Start
- Apr 2003
- Primary completion
- Apr 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in renal cell carcinoma (RCC), sponsored by Baylor College of Medicine. Primary endpoint: Number of patients with treatment related mortality at 100 days. Started Apr 2003; status: completed.
02
Drugs
alemtuzumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00073879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073879.